See also: Generic Xopenex
Xopenex HFA is a brand name of levalbuterol, approved by the FDA in the following formulation(s):
XOPENEX HFA (levalbuterol tartrate - aerosol, metered; inhalation)
Manufacturer: SUNOVION
Approval date: March 11, 2005
Strength(s): EQ 0.045MG BASE/INH [RLD]
Has a generic version of Xopenex HFA been approved?
No. There is currently no therapeutically equivalent version of Xopenex HFA available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xopenex HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for treating asthma using optically pure (R)-albuterol
Patent 5,362,755
Issued: November 8, 1994
Inventor(s): Barberich; Timothy J. & Young; James W.
Assignee(s): Sepracor, Inc.
The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with chronic administration of racemic albuterol.Patent expiration dates:
- March 25, 2013✓
- March 25, 2013
Method for treating asthma using optically pure R(-) albuterol
Patent 5,547,994
Issued: August 20, 1996
Inventor(s): Barberich; Timothy J. & Young; James W.
Assignee(s): Sepracor, Inc.
The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.Patent expiration dates:
- August 20, 2013✓
- August 20, 2013
Medicinal aerosol formulations
Patent 5,605,674
Issued: February 25, 1997
Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
Assignee(s): Riker Laboratories, Inc.
A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.Patent expiration dates:
- February 25, 2014✓
- February 25, 2014
Seals for use in an aerosol delivery device
Patent 5,836,299
Issued: November 17, 1998
Inventor(s): Kwon; Oh-Seung
Assignee(s): Minnesota Mining & Manufacturing Co.
A device for delivering an aerosol, comprising: a casing member, a valve stem, and a diaphragm. The diaphragm is made of an ethylene-propylene-diene rubber ("EPDM") and is stable to dimensional change when exposed to 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoroethane.Patent expiration dates:
- November 17, 2015✓
- November 17, 2015
Levalbuterol salt
Patent 7,256,310
Issued: August 14, 2007
Inventor(s): McGlynn; Paul & Bakale; Roger & Sturge; Craig
Assignee(s): Sepracor Inc.
Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.Patent expiration dates:
- October 8, 2024✓✓✓
- October 8, 2024
See also...
- Xopenex HFA Aerosol Consumer Information (Wolters Kluwer)
- Xopenex HFA Consumer Information (Cerner Multum)
- Xopenex HFA Advanced Consumer Information (Micromedex)
- Levalbuterol Aerosol Consumer Information (Wolters Kluwer)
- Levalbuterol Solution Consumer Information (Wolters Kluwer)
- Levalbuterol Consumer Information (Cerner Multum)
- Xopenex Pediatric Advanced Consumer Information (Micromedex)
- Levalbuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
- Levalbuterol AHFS DI Monographs (ASHP)
No comments:
Post a Comment